A Trial of BKM120 (a PI3K Inhibitor) in Patients With Triple Negative Metastatic Breast Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Jordi Rodon, MD
Hospital Universitario Vall d´Hebron
Principal Investigator - Jose Baselga, MD
Massachusetts General Hospital
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Hospital Universitario Vall D´hebron
Barcelona, Spain
- Hospital Universitario 12 de Octubre
Madrid, Spain
- Hospital Clínico Universitario de Valencia
Valencia, Spain
- Instituto Valenciano de Oncología
Valencia, Spain
- Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States
- Dana-Farber Cancer Institute
Boston, Massachusetts, United States
- Dana-Farber at Faulkner Hospital
Boston, Massachusetts, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Jun 2012
- Primary completion
- 31 Oct 2015
- Completion
- 31 Oct 2015
- Last update posted
- 28 Oct 2020
- Registered enrollment
- 50
- Registry id
- NCT01629615
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.